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Abstract
A common pathological hallmark of amyotrophic lateral sclerosis (ALS) and the related neurodegenerative disorder
frontotemporal dementia, is the cellular mislocalization of transactive response DNA-binding protein 43 kDa (TDP-43).
Additionally, multiple mutations in the TARDBP gene (encoding TDP-43) are associated with familial forms of ALS. While the
exact role for TDP-43 in the onset and progression of ALS remains unclear, the identification of factors that can prevent
aberrant TDP-43 localization and function could be clinically beneficial. Previously, we discovered that the oxidation
resistance 1 (Oxr1) protein could alleviate cellular mislocalization phenotypes associated with TDP-43 mutations, and that
over-expression of Oxr1 was able to delay neuromuscular abnormalities in the hSOD1G93A ALS mouse model. Here, to
determine whether Oxr1 can protect against TDP-43-associated phenotypes in vitro and in vivo, we used the same genetic
approach in a newly described transgenic mouse expressing the human TDP-43 locus harbouring an ALS disease mutation
(TDP-43M337V). We show in primary motor neurons from TDP-43M337V mice that genetically-driven Oxr1 over-expression
significantly alleviates cytoplasmic mislocalization of mutant TDP-43. We also further quantified newly-identified,
late-onset neuromuscular phenotypes of this mutant line, and demonstrate that neuronal Oxr1 over-expression causes a
significant reduction in muscle denervation and neuromuscular junction degeneration in homozygous mutants in parallel
with improved motor function and a reduction in neuroinflammation. Together these data support the application of Oxr1
as a viable and safe modifier of TDP-43-associated ALS phenotypes.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by the pro-
gressive loss of upper motor neurons in the cerebral cortex and
lower motor neurons in the brainstem and spinal cord, leading
to severe muscle wasting and death due to respiratory failure
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mutations in more than 20 genes associated with both familial
and some apparently sporadic forms; however, no identified
genetic contribution has been discovered in the majority (∼85%)
of cases. Despite this heterogeneity, over 95% of all ALS cases
share the pathological signature of mislocalized TDP-43 (43-
kDa transactive response DNA-binding protein) (2,3). Typically,
cytoplasmic aggregates containing hyper-phosphorylated and
ubiquitinated TDP-43 protein are found in affected motor neu-
rons in ALS, and in frontotemporal dementia (FTD), forming
a disease spectrum known as the TDP-43 proteinopathies (4).
In addition, mutations in the TARDBP gene, encoding TDP-43,
account for ∼5% of familial ALS (fALS), <1% of sporadic ALS, as
well as rare familial cases of FTD (5–8). To date, genetic studies
have revealed over 50 mutations in TDP-43 (9) and the majority
are clustered in the glycine-rich C-terminal domain (10).
TDP-43 is a ubiquitously expressed DNA/RNA-binding pro-
tein that functions in a wide range of cellular processes including
transcriptional regulation, RNA splicing and micro-RNA biogen-
esis (11,12). TDP-43 is predominantly found in the nucleus, how-
ever, under conditions of cellular stress, such as oxidative stress
observed in ALS, TDP-43 relocalizes to the cytoplasm where
it facilitates the formation and dissociation of stress granules
(13–15). Whether the process of TDP-43 mislocalization is itself
required for the onset or progression of ALS is still debated.
Therefore, a complex picture is emerging whereby loss of normal
nuclear function may act in combination with aberrant cyto-
plasmic toxicity. As such, although the molecular mechanisms
underlying the role TDP-43 in ALS are still under investigation,
factors that are able to alleviate the mislocalization and/or other
aberrant roles of TDP-43 mutants in neuromuscular function
may provide therapeutic potential.
Cellular studies have begun to reveal the properties of indi-
vidual TDP-43 mutations, with over-expression typically driving
reproducible cytoplasmic mislocalization, thus promoting the
search for modifiers of this fundamental feature of TDP-43
biology in vitro (16). For instance, oxidation resistance 1 (OXR1) is
a member of a family of proteins containing the TLDc domain
that is protective against oxidative stress-related insults (17–
19). During a screen for protein interactors in neuronal cells, we
identified TDP-43 as an Oxr1 binding partner (20). Interestingly,
over-expression of a short functional isoform of Oxr1 (Oxr1-
C)—consisting of almost exclusively the TLDc domain—reduced
cytoplasmic mislocalization and aggregation of TDP-43 mutants
where binding to Oxr1 was preserved (M337V and Q331K),
suggesting that Oxr1 has the potential to alleviate TDP-43-
associated pathology such as mitochondrial dysfunction and
oxidative stress-induced apoptosis (20). Further evidence that
Oxr1 is protective against ALS-associated phenotypes was
revealed during an in vivo study of the hSOD1G93A mouse model,
where neuronal over-expression of Oxr1 extended survival of
mutants while significantly delaying spinal cord and muscle
pathology, including reducing neuroinflammation (21). Crucially,
over-expression of Oxr1 was not detrimental to the mice,
indicating that Oxr1 could be a positive candidate for the
modification of mutant TDP-43 function in vivo (21).
To date, a range of rodent models expressing TDP-43
mutations has been generated in an attempt to understand
the pathobiology of TDP-43 dysfunction. In general, mouse
models that have utilized expression of a TDP-43 transgene
have recapitulated certain ALS-associated phenotypes such
as motor dysfunction, although toxicity driven by artificial
promoters generating non-physiological levels of the protein
likely explains the variable severity of the pathologies observed
(22–31). For example, mice over-expressing neuronal TDP-43
containing the ALS-associated M337V mutation show severe
motor neuron loss, neuromuscular junction (NMJ) degeneration
and premature death by 1 month of age (30,31), whereas mice
hemizygous for the same transgene display a far-less severe
motor phenotype (32). In order to circumvent the inherent
limitations of these approaches, mice with a single copy of either
a wild-type (WT) or mutant M337V human bacterial artificial
chromosome (BAC) containing the entire TDP-43 locus were
generated recently (16,33). Expression of TDP-43M337V from the
native human promoter leads to progressive motor impairment
and disruption of the NMJ from 6 months of age, thus facilitating
longitudinal studies of the pre- and post-symptomatic stages of
pathogenesis (33); importantly, mice expressing the identical
WT BAC (TDP-43WT) display no pathological or behavioural
abnormalities at any timepoint, demonstrating the specific
pathological effects of the mutant transgene (33).
Here, given that Oxr1 over-expression can delay pathogenesis
in the hSOD1G93A model (21) and reduce mislocalization and
aggregation of mutant TDP-43M337V in vitro (20), we aimed to
investigate the neuroprotective function of Oxr1 in the context
of in vivo expression of TDP-43M337V in this mouse model. First, we
demonstrate that cytoplasmic mislocalisation of mutant TDP-43
in primary motor neurons from TDP-43M337V mutants is allevi-
ated by Oxr1 over-expression. We go on to show that neuronal
over-expression of Oxr1 significantly improves motor function
as well as newly-characterized neuromuscular, muscular and
neuroinflammatory phenotypes in TDP-43M337V mice. Together
these data demonstrate the promise of Oxr1 as a valuable mod-
ifier of TDP-43-associated ALS phenotypes.
Results
Genetic over-expression of Oxr1 reduces aberrant
TDP-43 mislocalization in primary motor neurons from
TDP-43M337V/− mice.
Our previous cellular data demonstrated that Oxr1 can positively
influence the mislocalization of the M337V mutant form of TDP-
43 when both are over-expressed exogenously (20). Here, we
began by investigating whether this potentially important aspect
of Oxr1 function would also be observed in a mammalian genetic
system using primary motor neuron cultures where high levels
of exogenous expression were not required. For this purpose,
we selected the recently described mouse line carrying a sin-
gle copy of a human TDP-43M337V BAC transgene (33). Primary
motor neurons derived from hemizygous (TDP-43M337V/−) but
not control (TDP-43WT/−) embryonic day (E)13.5 embryos have
been shown to display robust mislocalization of mutant TDP-43
without exogenous cellular stress, thus providing a novel genetic
assay for studying TDP-43 mislocalization and aggregation (33).
To investigate whether Oxr1 is a genetic modifier of this key
mutant TDP-43-associated phenotype phenotype, homozygous
TDP-43M337V/M337V mice were crossed with mice hemizygous for a
full-length Oxr1 cDNA transgene driven by a neuronal promoter
(Oxr1Prnp/−) (21). We chose this breeding strategy such that all the
embryos used were experimental, either TDP-43M337V/− or TDP-
43M337V/−/Oxr1Prnp/− littermates. Of note, the expression of the
Oxr1 transgene has already been shown to occur on or before
E13.5 (21), and only cells positive for the motor neuron marker
SMI32 were used for subsequent analysis (34). After 7 days in
culture to reach a sufficient differentiation state, we quantified
the localization of the human-specific pool of TDP-43M337V in
motor neurons using an antibody directed against its C-terminal
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a significant proportion of mutant TDP-43 was detected in the
cytoplasm of motor neurons from TDP-43M337V/− mice, although
interestingly this proportion was significantly reduced in TDP-
43M337V/−/Oxr1Prnp/− cells (Fig. 1B; P = 0.0007). To further inves-
tigate this phenotype, the proportion of motor neurons that
contained predominantly cytoplasmic mutant TDP-43 was also
quantified, revealing a striking 20-fold reduction in cells from
TDP-43M337V/−/Oxr1Prnp/− animals compared with motor neurons
from TDP-43M337V/− mice (Fig. 1C; P = 0.0001). Together, these data
not only confirm the utility of the TDP-43M337V mouse line for the
quantification of mislocalization phenotypes in primary cells,
but also reveal that over-expression of Oxr1 reduces the aber-
rant mislocalization of mutant TDP-43 in TDP-43M337V/− motor
neurons, in agreement with our earlier in vitro studies (20).
Over-expression of Oxr1 significantly improves motor
function in TDP-43M337V/M337V mice
The data above further support the findings that Oxr1 can
improve mutant TDP-43 mislocalisation in vitro; however, as
we have previously observed the alleviation of neuromuscular
dysfunction in the hSOD1G93A mouse model using Oxr1 (21), we
wanted to investigate whether this positive modifying effect
extended to the mitigation of TDP-43-associated phenotypes
in vivo. Therefore, given the results from the primary motor
neurons above, our next aim was to quantify longitudinal
behavioural and neuromuscular phenotypes in the same
TDP-43 BAC transgenic model in the presence or absence
of Oxr1 over-expression. TDP-43M337V/−/Oxr1Prnp/− mice were
crossed with TDP-43M337V/− mice to generate experimental
cohorts of four genotypic combinations: non-transgenic WTs
(NTg), those carrying the Oxr1 transgene alone (Oxr1Prnp/−),
homozygous TDP-43 mutants (TDP-43M337V/M337V) and mice with
both transgenes present (TDP-43M337V/M337V/Oxr1Prnp/−). Using
lysates from the spinal cord, we confirmed that that TDP-
43M337V/M337V express the Ypet-tagged human TDP-43M337V protein
at levels below that of endogenous mouse TDP-43 as previously
described (33) (Supplementary Material, Fig. 1A). In addition,
we showed that that Oxr1Prnp/− and TDP-43M337V/M337V/Oxr1Prnp/−
mice express HA-tagged Oxr1 approximately 7-fold higher than
endogenous Oxr1 levels, consistent with previous studies of this
specific mouse line (Supplementary Material, Fig. 1B; P = 0.0003)
(21). Furthermore, given that Oxr1 has been shown to be induced
under a range of stress-associated conditions (17), endogenous
Oxr1 protein levels were quantified in the spinal cord, however,
the expression was not increased in TDP-43M337V/M337V mutants
compared to controls (Supplementary Material, Fig. 1C).
Homozygous TDP-43M337V/M337V mutants have been shown
previously to display progressive motor dysfunction from
6 months of age (33); therefore, we used a combination of rotarod
and grip strength testing up to 18 months of age to quantify any
potential phenotypic modification by Oxr1 over-expression in
both males and females (details of the experimental cohorts are
shown in Supplementary Material, Table 1). Up to 6 months of
age, mice of all four genotypes demonstrated no difference in
motor co-ordination or muscle strength (Fig. 2A–D). By 9 months
of age, however, male TDP-43M337V/M337V mice begin to show
a progressive decrease in motor coordination and muscle
strength compared to the control lines as previously described
(Fig. 2A and C) (33). This difference in performance did not
reach significance compared with every one of the additional
genotypes at 9 to 18 months of age, yet importantly, male TDP-
43M337V/M337V/Oxr1Prnp/− mice performed significantly better than
TDP-43M337V/M337V mutants in one or both of the tests at 9, 12, 15
and 18 months of age (Fig. 2A and C; rotarod: P = 0.021, P = 0.026,
P = 0.0008, 9–15 months; grip strength: P = 0.0071, P = 0.028,
P = 0.037, 12–18 months). Similar to observations in male mice,
female TDP-43M337V/M337V/Oxr1Prnp/− mice displayed a significant
improvement in motor coordination and muscle strength at
12 to 18 and 9 to 12 months of age, respectively, as compared
to female TDP-43M337V/M337V littermates (Fig. 2B and D; rotarod:
P = 0.0084, P = 0.0061, P = 0.0019, 12–18 months; grip strength:
P = 0.015, P = 0.036, 9–12 months).
As body weight can influence performance in these
types of motor-associated tasks (35), we also took weight
measurements from the same cohorts of male and female
animals (Fig. 2E and F). Critically, these data demonstrated
that TDP-43M337V/M337V and TDP-43M337V/M337V/Oxr1Prnp/− mice did
not show any difference in weight at 9 to 18 months of age
within either sex group, suggesting that this was not a factor
that could explain the improvement in performance of TDP-
43M337V/M337V/Oxr1Prnp/− animals versus homozygous TDP-43M337V
mutants (Fig. 2A–D). Interestingly, at 12 (P = 0.0025), 15 (P = 0.0011)
and 18 (P = 0.0009) months of age, male TDP-43M337V/M337V mutants
displayed a significantly decreased body weight compared
to NTg WT controls (Fig. 2E); this may explain the lack of
statistically significant differences between TDP-43M337V/M337V
and NTg mice with regards to motor coordination and muscle
strength tests at 12 to 18 months of age, as heavier control mice
may be less able to perform the tasks (35). It is noteworthy that,
despite a trend towards the NTg females being heavier, there
was a significant increase in weight between the female NTg
and TDP-43M337V/M337V cohort only at 15 months of age (P = 0.041)
and overall less of a deterioration of performance in NTg mice
(Fig. 2F). Therefore, taken together, these data suggest that
over-expression of Oxr1 in neurons is able to improve motor
coordination and muscle strength in TDP-43M337V/M337V mice.
Over-expression of Oxr1 significantly improves muscle
denervation and NMJ degeneration in TDP-43M337V/M337V
mice
Muscle denervation and degeneration of the NMJs is a major
defining feature of ALS, and may occur prior to lower motor
neuron loss (36–38). Furthermore, it has been demonstrated
that rodent models over-expressing mutant TDP-43M337V display
muscle denervation and abnormal NMJ morphology (39,40).
In the TDP-43M337V/M337V mutant studied here, a small but
significant increase in the number of partially denervated
NMJs was reported at 12 months of age in hind-paw lumbrical
muscles (33). Therefore, we next examined whether Oxr1 over-
expression was able to recover or delay this specific disease-
relevant phenotype, and importantly, at a more advanced
symptomatic time-point than had been previously studied
in this line. Hind-paw lumbrical muscles from 18-month-
old male mice were stained with antibodies for presynaptic
nerve terminals (SV2 and 2H3) and post-synaptic acetylcholine
receptors located on the motor endplate (α-BTX). The number
of NMJs that were fully innervated, partially innervated
or fully denervated were then quantified (Fig. 3A–D). We
observed that TDP-43M337V/M337V mice show a significant decrease
in the number of fully innervated NMJs at 18 months of
age compared with both the NTg and Oxr1Prnp/− controls
(Fig. 3B; P < 0.001 versus both control lines). In addition, TDP-
43M337V/M337V mice displayed an approximately 10-fold increase







g/article/28/21/3584/5559948 by guest on 26 July 2021
Human Molecular Genetics, 2019, Vol. 28, No. 21 3587
Figure 1. Genetic over-expression of Oxr1 reduces mislocalisation of mutant TDP-43 in TDP-43M337V/− primary motor neurons. (A) Representative images of SMI32-
positive primary motor neurons from TDP-43M337V/− and TDP-43M337V/−/Oxr1Prnp/− mice stained with anti-GFP to quantify Ypet-tagged mutant TDP-43M337V. (B)
Motor neurons from TDP-43M337V/−/Oxr1Prnp/− mice display a significant decrease in the proportion of cytoplasmic mutant TDP-43 compared to TDP-43M337V/− mice.
(C) Motor neurons from TDP-43M337V/−/Oxr1Prnp/− animals show a significant decrease in the proportion of motor neurons with >50% cytoplasmic mutant TDP-43
compared with TDP-43M337V/− mice. Values are shown as the mean ± SEM. N = 45–60 motor neurons quantified per individual embryonic motor neuron preparation,
N = 6 embryos quantified per genotype across two independent litters; ∗∗∗P < 0.001, Unpaired student’s t-test. Scale bar: 20 μm.
compared with the same control lines (Fig. 3C and D; P < 0.0001
versus both control lines). Importantly, we also observed a
significant increase in the number of fully innervated NMJs
in TDP-43M337V/M337V/Oxr1Prnp/− mice versus TDP-43M337V/M337V
littermates (Fig. 3B; P = 0.0082). Consistent with these data,
we found a significant 2- to 4-fold decrease in the num-
ber of partially innervated (P = 0.025) and vacant (P = 0.0008)
NMJs compared to TDP-43M337V/M337V mutants (Fig. 3C and D).
Together, these data not only reveal a robust lumbrical
muscle denervation phenotype in TDP-43M337V/M337V mice at
18 months of age, but also that this key disease-relevant
phenotype can be significantly rescued by over-expression of
Oxr1.
During the progression of ALS, muscle fibers degenerate
and regenerate, which causes alterations in the size of post-
synaptic motor endplates (41); hence, immunostaining of these
structures can be used as a secondary indicator of muscle
denervation. Therefore, we went on to investigate the area
of post-synaptic endplates from lumbrical muscle NMJs in
our experimental cohorts at 18 months of age (Fig. 4A). The
average end-plate area was ∼25% lower in male TDP-43M337V/M337V
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Figure 2. Over-expression of Oxr1 improves motor function and muscle strength in TDP-43M337V/M337V mice. Longitudinal rotarod testing shows a significant
improvement in motor coordination for both male (A) and female (B) TDP-43M337V/M337V/Oxr1Prnp/− mice compared to male and female TDP-43M337V/M337V mice,
respectively. Grip strength analysis reveals a significant improvement in muscle strength for both male (C) and female (D) TDP-43M337V/M337V/Oxr1Prnp/− mice
compared with male and female TDP-43M337V/M337V mice, respectively. TDP-43M337V/M337V/Oxr1Prnp/− mice show no significant difference in weight at 9 to 18 months
compared to TDP-43M337V/M337V mice for both male (E) and female (F) cohorts. Values are shown as the mean ± SEM. Sample sizes for each cohort are described in
Supplementary Material, Table 1. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001; one-way ANOVA, with Dunnett’s multiple comparison test comparing each group as per the graph
legend (green/asterisks, TDP-43M337V/M337V/Oxr1Prnp/−, blue/circles: Oxr1Prnp/−, black/stars: NTg) to TDP-43M337V/M337V mice.
endplate degeneration in homozygous mutants, although this
did not reach significance (Fig. 4B; P = 0.067, P = 0.071 versus
NTg and Oxr1Prnp/−, respectively). Importantly, however, TDP-
43M337V/M337V/Oxr1Prnp/− mice displayed a very similar average
post-synaptic endplate area compared to both NTg and
Oxr1Prnp/− animals, with a significant increase compared to TDP-
43M337V/M337V mutants (P = 0.031), suggesting that motor endplate
degeneration in TDP-43M337V/M337V mutants can be rescued by
over-expression of Oxr1 (Fig. 4B).
To confirm that these pathological data are consistent
in females, we carried out an equivalent set of NMJ anal-
yses from 18-month-old female TDP-43M337V/M337V and TDP-
43M337V/M337V/Oxr1Prnp/− littermates. Similar to the data observed
in males, female TDP-43M337V/M337V/Oxr1Prnp/− mice display a
significant increase in fully innervated NMJs (P = 0.044) and sig-
nificant decrease in vacant NMJs (P = 0.0077) compared to TDP-
43M337V/M337V littermates (Supplementary Material, Fig. 2A–D)
. In addition, the average post-synaptic motor endplate area
was significantly greater in female TDP-43M337V/M337V/Oxr1Prnp/−
mice compared with female TDP-43M337V/M337V mutants
(Supplementary Material, Fig. 2E and F; P = 0.019). Together, these
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Figure 3. Over-expression of Oxr1 improves neuromuscular innervation in TDP-43M337V/M337V mutants. (A) Representative images showing lumbrical NMJs from male
NTg, Oxr1Prnp/−, TDP-43M337V/M337V and TDP-43M337V/M337V/Oxr1Prnp/− mice at 18 months of age. Levels of denervation were assessed by determining the overlap
between pre-synaptic (2H3/SV2) and post-synaptic (α-BTX) staining. NMJs were scored as fully innervated (white arrow), partially innervated (blue arrow), or vacant
(purple arrow). (B–D) Denervation analysis reveals a significant decrease in fully innervated NMJs and a significant increase in partially innervated and vacant NMJs in
TDP-43M337V/M337V mice, which is rescued by over-expression of Oxr1. Values are shown as the mean ± SEM. N = 3–6 each genotype, N > 58 NMJs per mouse. ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.001; one-way ANOVA with Dunnett’s multiple comparison test comparing each group to TDP-43M337V/M337V mice. Scale bar: 20 μm.
lumbrical muscle denervation and NMJ degeneration in TDP-
43M337V/M337V mice at 18 months of age.
Previous neuropathological analysis of TDP-43M337V/M337V
mutants reported no detectable mislocalization of either
endogenous or human mutant TDP-43 up to 24 months of age
and no loss of motor neurons in the spinal cord at 12 months
(33). We independently quantified both of these parameters
at 18 months of age in our experimental cohort, and in
agreement, found no significant decrease in the number of
lower motor neurons in the spinal cord of TDP-43M337V/M377V
mice or an increase in the number of motor neurons with
detectable cytoplasmic TDP-43 aggregates compared to controls
(Supplementary Material, Fig. 3A and B). These data confirm
that the neuromuscular defects we observed in TDP-43M337V/M337V
mice occur in the absence of detectable TDP-43 aggregation in
lower motor neurons.
Over-expression of Oxr1 improves muscle pathology
observed in TDP-43M337V/M337V mutants
Muscle atrophy is another hallmark of ALS pathology that occurs
concomitantly with muscle denervation and NMJ degeneration
(42–44). Therefore, given the muscle denervation we observed
in TDP-43M337V/M337V mutants, we next determined whether
detectable muscle pathology occurs at the same timepoint,
as this has not been reported previously in this line. In ALS,
muscles that are largely composed of fast-twitch fibres appear
to be more vulnerable to degeneration prior to motor neuron
loss (43,44). Thus we chose to begin by examining tibialis
anterior (TA) muscles as these contain a high proportion of
fast-twitch fibres compared to the gastrocnemius and soleus
muscles in C57BL6/J mice (45). Initially, we observed no overt
signs of muscle atrophy, such as decreased fibre number, in TA
muscle from TDP-43M337V/M337V mutants or any of the control
strains (Fig. 5A). However, quantification of centrally-nucleated
fibres, a marker of muscle fibre degeneration and subsequent
regeneration or myopathy revealed a significant increase in TDP-
43M337V/M337V mice compared to NTg and Oxr1Prnp/− controls at
18 months of age (Fig. 5B; P = 0.011, P = 0.026 versus NTg and
Oxr1Prnp/−, respectively). Moreover, and in-line with our NMJ
data, the number of centrally nucleated fibres was significantly
lower in TDP-43M337V/M337V/Oxr1Prnp/− mice compared to TDP-
43M337V/M337V mutants (Fig. 5B, P = 0.039), suggesting that over-
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Figure 4. Over-expression of Oxr1 improves post-synaptic NMJ integrity in TDP-43M337V/M337V mutants. (A) Representative images of motor endplates used to measure
post-synaptic area from male NTg, Oxr1Prnp/−, TDP-43M337V/M337V and TDP-43M337V/M337V/Oxr1Prnp/− mice at 18 months of age. (B) Average motor endplate area is
reduced in TDP-43M337V/M337V mice, and is rescued by over-expression of Oxr1. Values are shown as the mean ± SEM. N = 3–6 each genotype, N = 30–50 NMJs per mouse.
∗P < 0.05; one-way ANOVA with Dunnett’s multiple comparison test comparing each group to TDP-43M337V/M337V mice. Scale bar: 20 μm.
TDP-43M337V/M337V line. Next, we carried out the same analysis on
the soleus muscle from all four genotypes (Fig. 5A). Although a
smaller percentage of centrally nucleated fibres were detected
overall compared to the TA, there was a significant increase in
TDP-43M337V/M337V mice compared with controls, and significantly
fewer in TDP-43M337V/M337V/Oxr1Prnp/− mice compared with TDP-
43M337V/M337V mutants (Fig. 5C; P = 0.020, P = 0.033, P = 0.041 versus
NTg, Oxr1Prnp/− and TDP-43M337V/M337V/Oxr1Prnp/−, respectively).
To investigate this further, we went on to determine whether
there was evidence for muscle fibre-type alterations in TDP-
43M337V/M337V animals, such grouping or switching to differ-
ent fibre-types as observed in human ALS and neurogenic
myopathies due to muscle remodelling (46). Quantitative ATPase
histological staining was carried out to delineate between slow
(type I) and fast (type II) fibre types based-on histological pH-
driven inhibition of myosin-ATPase enzymes. Despite evidence
for muscle fibre myopathy and/or regeneration in TA muscle
from TDP-43M337V/M337V mice, virtually no type I muscles were
observed in any of the four genotypes as expected in normal,
aged samples (47) (Fig. 5A). Therefore, next we carried out fibre-
type analysis on the soleus muscle of the same mice as this
muscle group consists of a larger proportion of type I fibres
(45). Quantification using a pH 4.2 pre-incubation buffer to
stain type I fibres, alongside a pH 10.3 buffer to stain type II
fibres in a reciprocal manner, showed there was no significant
change in the overall proportion of fibre types between the
genotypes (Fig. 5D and E); interestingly, however, examples of
fibre-type grouping were only observed in TDP-43M337V/M337V
samples (Fig. 5A), suggesting that muscle remodelling due to
denervation and reinnervation occurs in TDP-43M337V/M337V mice
that can be improved by Oxr1 over-expression.
Neuroinflammation occurs in the spinal cord of
TDP-43M337V/M337V mice and is alleviated by Oxr1
over-expression
Neuroinflammation is predicted to play an active role during
disease progression in ALS patients, and has been observed
in mouse models over-expressing ALS-associated proteins
including M337V mutant TDP-43 (31,48–50). In the TDP-
43M337V/M337V BAC transgenic line at 12 months of age, ionized
calcium binding adaptor molecule 1 (Iba1) immunostaining
indicated no overt microgliosis in the spinal cord (33). However,
we wanted to assess whether either astrogliosis or microgliosis
could be observed at the same later symptomatic timepoint
as our other pathological observations, but also not be
confounded by motor neuron death. Therefore, lumbar spinal
cord sections were immunostained for Iba1 and glial fibrillary
acidic protein (GFAP) from TDP-43M337V/M337V mice and NTg
controls at 18 months of age. We observed that the ventral
horns of TDP-43M337V/M337V mice display significantly increased
immunoreactivity for Iba1, both in terms of the number
of immunopositive cells (Fig. 6A and B; P = 0.0064, P = 0.0088
versus NTg and Oxr1Prnp/−, respectively) and immunopositive
staining area (Fig. 6A and C; P = 0.0075, P = 0.0073 versus NTg and
Oxr1Prnp/−, respectively). For GFAP, increased immunoreactivity
was also observed compared to the control lines (Fig. 6A and D;
P = 0.033, P = 0.041 versus NTg and Oxr1Prnp/−, respectively),
indicative of an increased neuroinflammatory response in
mutant animals.
It has been demonstrated previously that over-expression
of Oxr1 in neurons of hSOD1G93A mice decreased astrogliosis
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Figure 5. Over-expression of Oxr1 improves muscle pathology in male TDP-43M337V/M337V mice. (A) Representative images of H&E-stained TA and soleus muscle fibre
cross-sections from NTg, Oxr1Prnp/−, TDP-43M337V/M337V and TDP-43M337V/M337V/Oxr1Prnp/− mice at 18 months of age. Examples of centrally nucleated fibres are
indicated (arrowheads). Representative images of ATPase staining for muscle fibre types using the preincubation pH conditions as indicated are also shown; pH 4.2,
type I fibres dark staining and type II fibres light staining; pH 10.3, type I fibres light staining and type II fibres dark staining. (B and C) The percentage of centrally
nucleated fibres per section is significantly increased in TDP-43M337V/M337V mice in both TA (B) and soleus (C), which is rescued by over-expression of Oxr1. (D and E)
Quantitation of fibre-type staining in the soleus reveals no significant differences in the proportions between genotypes, although fibre-type grouping is observed in
TDP-43M337V/M337V mice (A). Values are shown as the mean ± SEM. N = 3–5 male animals per genotype. ∗P < 0.05, One-way ANOVA with Dunnett’s multiple comparison
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Figure 6. Neuroinflammation in lumbar spinal cords from male TDP-43M337V/M337V mice is alleviated by Oxr1 over-expression. (A) Representative images of spinal cord
sections stained with anti-Iba1 and anti-GFAP from male NTg, Oxr1Prnp/−, TDP-43M337V/M337V and TDP-43M337V/M337V/Oxr1Prnp/− mice. (B and C) Quantification of
the number of immunopositive cells and immunopositive area for anti-Iba1 reveals increased microgliosis in TDP-43M337V/M337V mice that is significantly reduced in
TDP-43M337V/M337V/Oxr1Prnp/− animals. (D) Quantification of the immunopositive area for anti-GFAP signal reveals increased astrogliosis in TDP-43M337V/M337V mice
that is significantly reduced in TDP-43M337V/M337V/Oxr1Prnp/− animals. (B–D) Values are shown as the mean ± SEM. N = 3–5 animals per genotype; ∗P < 0.05, ∗∗P < 0.01;
One-way ANOVA with Dunnett’s multiple comparison test comparing each group to TDP-43M337V/M337V mice. Scale bar: 100 μm.
able to influence neuroinflammation in vivo (21). Therefore,
in parallel, we determined whether neuronal over-expression
of Oxr1 could ameliorate the neuroinflammation observed
in TDP-43M337V/M337V mice. Interestingly, we observed a sig-
nificant 25% decrease in the number of Iba1 immunoposi-
tive cells (Fig. 6A and B; P = 0.016) and immunoreactive area
(Fig. 6A and C; P = 0.028) from TDP-43M337V/M337V/Oxr1Prnp/− spinal
cord sections compared to homozygous mutants. The GFAP
immunoreactive staining area was also significantly decreased
in TDP-43M337V/M337V/Oxr1Prnp/− compared to TDP-43M337V/M337V
littermates (Fig. 6A and D; P = 0.024 versus TDP-43M337V/M337V/
Oxr1Prnp/−). Taken together, these data indicate that an induction
of the inflammatory response occurs in the TDP-43M337V/M337V
mutant spinal cord, with neuronal Oxr1 over-expression
facilitating a dampening of the observed microgliosis and
astrogliosis.
Oxr1 binds to TDP-43 in vivo
We have demonstrated previously that over-expression of
Oxr1 in vitro alongside exogenous M337V mutant TDP-43 can
improve TDP-43 mislocalization under oxidative stress, and
this phenomenon may rely on an interaction between the two
proteins (20). Thus, our new data in primary motor neurons from
TDP-43M337V/−/Oxr1Prnp/− mice (Fig. 1) is important, as it further
supports a role for Oxr1 in preventing TDP-43 mislocalisation
in a mammalian genetic system. Therefore, to determine
whether binding between TDP-43 and Oxr1 occurs in vivo, co-
immunoprecipitation (IP) experiments were carried out from
spinal cord tissue. Using a pan-TDP-43 antibody, both the full-
length Oxr1 isoform (Oxr1-FL) and the shorter Oxr1-C isoform
were co-immunoprecipitated from TDP-43M337V/M337V/Oxr1Prnp/−
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Figure 7. Oxr1 binds to TDP-43 in vivo. Co-IP in spinal cord tissue from a TDP-
43M337V/M337V/Oxr1Prnp/− mouse using a pan-TDP-43 antibody (left lanes) and
non-specific IgG (right lanes). Lower panels represent input loading controls.
Antibodies used for western blotting are indicated. The Oxr1 antibody recognises
both the TLDc domain-containing endogenous full-length Oxr1-(FL) and the
shortest isoform Oxr1-(C).
between TDP-43 and the HA-tagged Oxr1 transgene, we also
immunoblotted with an anti-HA antibody. HA-tagged Oxr1
successfully co-immunoprecipitated with TDP-43 with a much
higher efficiency than the control (IgG only) (Fig. 7). Together,
these data demonstrate that TDP-43 can bind to two functionally
important endogenous Oxr1 isoforms in vivo, as well as the Oxr1
transgene overexpressed in TDP-43M337V/M337V/Oxr1Prnp/− mice.
Discussion
The central role for TDP-43 in ALS and FTD pathophysiology,
alongside the discovery of causative mutations in fALS, has
prompted the generation of multiple rodent TDP-43 disease
models. Yet the broad phenotypic variation between mutant
lines likely reflects non-specific toxicity of TDP-43 transgenes
driven by artificial promoters (24,51). Consequently, there has
been an effort to generate models that express the protein
at more physiologically-relevant levels using endogenous pro-
moters. Here, we have studied one such novel transgenic line
containing the entire human TDP-43 locus carrying a pathogenic
M337V mutation. Experimental animals thus express the mutant
human protein in addition to endogenous Tdp-43, a situation
akin to the dominant nature of M337V mutations observed in
ALS (52). Our own additional pathological studies of these TDP-
43M337V/M337V mice revealed significant denervation at the NMJ
at a later timepoint than had been studied previously (33), in
addition to newly discovered hind-limb muscle pathology and
neuroinflammation in the lumbar spinal cord. These findings
further demonstrate the utility of this mouse line for the study
of disease-relevant pre-symptomatic interventions in a model
where the neuromuscular system has developed normally prior
to neurodegeneration, as occurs in human ALS.
We went on to show that the neuromuscular defects we
observed in TDP-43M337V/M337V mice at 18 months of age occur
in the absence of detectable TDP-43 aggregation in lower motor
neurons. These data are in agreement with a number of other in
vivo models that have analysed the same pathogenic mutation.
For example, induction of a motor neuron-specific TDP-43M337V
transgene in neonatal rats results in motor dysfunction, rapid
motor neuron loss, NMJ degeneration and premature death by
3 months of age, yet without the presence of TDP-43-positive
aggregates in lower motor neurons (39). Similarly, driving hTDP-
43M337V expression using a neuronal Thy1.2 promoter results in
dose-dependent neuromuscular defects and early mortality in
mice; however, TDP-43 mislocalization was not associated with
these particular phenotypes (53). Most recently, a mouse knock-
in model has been described in which the M337V mutation
was introduced into the endogenous mouse Tdp-43 locus
(48). Interestingly, the phenotype of mutants carrying either
one or two copies of this particular mutant knock-in allele
is somewhat subtler than the human BAC model we have
utilized here. For example, homozygous M337V knock-in mice
displayed a small but significantly reduced innervation of TA
muscles, although this was only detectable at 30 months of
age. In addition, an increase in gliosis was described in the
lumbar spinal cord at 24 months in homozygous M337V knock-
in mice compared to controls, although no mislocalization of
TDP-43 was detected (48). Hence these findings add to the
growing body of evidence suggesting TDP-43 aggregation is
not primarily responsible for the onset of disease symptoms in
ALS. Although we cannot rule-out the presence of mislocalized
TDP-43 species that are beyond antibody detection levels in
TDP-43M337V/M337V mice, neither neurofilament, peripherin nor
p62-containing aggregates were reported previously in this BAC
transgenic model up to 24 months of age (33). It is noteworthy
that the mouse endogenous knock-in M337V allele rescued
the lethality of a Tdp-43 knockout mutant, suggesting this
mutation is not completely a loss-of-function mutation (48).
In contrast, a similar experiment revealed that the human TDP-
43M337V BAC transgene did not rescue mice lacking endogenous
Tdp-43 (33); this difference is likely largely due to the lower
relative expression level of the BAC-derived mutant TDP-43
compared with endogenous protein (Supplementary Material,
Fig. 1A), although different functional targets of the human and
mouse protein that are critical for development may also play a
role.
Previously we successfully utilized over-expression of Oxr1
to delay neuromuscular abnormalities in the hSODG93A mouse
model (21). Here, using the same genetic approach to over-
express Oxr1 in neurons, we demonstrate a striking reduction
in lumbrical muscle denervation and NMJ degeneration in
TDP-43M337V/M337V/Oxr1Prnp/− mice versus homozygous TDP-
43M337V mutants. Considering that lumbrical muscles in the
paws are directly involved in grip strength and locomotion, the
protection Oxr1 provides against NMJ degeneration and muscle
denervation likely explains why we also observe significantly
improved motor function in TDP-43M337V/M337V/Oxr1Prnp/− mice
compared with TDP-43M337V/M337V littermates. Although the
molecular function of OXR1 is still under investigation, there is
growing evidence that this protein can protect against oxidative
stress via the modulation of antioxidants and related cell death-
associated pathways (17,54–56). Indeed, there is evidence that
presynaptic nerve terminals at the NMJ are sensitive to such
reactive oxygen species, as under oxidative stress conditions
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An additional hypothesis associated with Oxr1’s neuro-
protective properties in vivo relates to the marked delay in
neuroinflammation observed in the spinal cord of hSOD1G93A
mutants expressing exogenous Oxr1 (21). One possibility
linking Oxr1 to inflammation would be that Oxr1 affects the
function of proteins participating in the immune response.
For example, we recently demonstrated that Oxr1 modulates
the activity of glucose-6-phosphate isomerase (Gpi1) and
peroxiredoxin 2 (Prdx2), which can be secreted by neurons to
activate glial cells and thus contribute to the inflammatory
response. (55,58–60). Another possibility would be that Oxr1
over-expression leads to a global reduction of ROS levels
within neurons, leading to a reduction in proinflammatory
signals released by neurons, which is often associated with
sustained oxidative stress conditions and an inhibition of
inflammation in the central nervous system (61). In the TDP-
43M337V/M337V model we observed an increase in activated
microglia and astrocytes at 18 months of age in the spinal
cord. We provide evidence, based on immunohistochemistry,
that the activation of microglia and astrocytes was significantly
reduced by the presence of exogenous Oxr1, although this was
not completely prevented by neuronal Oxr1 over-expression.
This discrepancy could be explained by a potential specificity
of action of Oxr1 on sub-populations of activated glial cells.
Indeed, both the phenotype and function of both microglia
and astrocytes evolve during the immune response from cut
neuroprotective to a pro-inflammatory cut phenotype (62,63).
Therefore, further studies would be required to characterize
the ‘reactive profile’ of glial cells in hTDP-43M337V mice and
to determine the precise influence of Oxr1 on microglia and
astrocytes during inflammation. Nevertheless, we have shown
here that the positive effects of Oxr1 over-expression are
not specific to mutant SOD1-associated phenotypes but also
beneficial to other forms of ALS, further supporting the efficacy
of Oxr1 as a valuable modifier of neuromuscular dysfunction
in vivo.
An additional feature of this hTDP-43M337V model is the
presence of a robust TDP-43 mislocalisation phenotype in
cultured motor neurons (16,33). Why TDP-43 shows a propensity
to aggregate in culture but not in the spinal cord of hTDP-
43M337V mice remains unclear, although this in-part likely
reflects the lack of supporting cells in vitro that are present
in vivo (64). We were able to take advantage of this valuable
experimental system and demonstrate that genetically-driven
over-expression of Oxr1 leads to a significant reduction in
mislocalized mutant TDP-43 in motor neurons. Furthermore, we
demonstrated an interaction between TDP-43 and endogenous
Oxr1 isoforms in addition to transgenic over-expressed Oxr1
in the spinal cord. These findings extend our former data in
N2a cells, where TDP-43 mutants that were able to bind to
Oxr1, including TDP-43M337V, showed a tendency to relocate
to the nucleus when Oxr1 was over-expressed (20). Therefore,
our hypothesis is that an interaction with Oxr1 either disrupts
aggregate formation or promotes the correct cellular trans-
portation of TDP-43. The importance of the nucleocytoplasmic
transport machinery to this key aspect of TDP-43 biology is
becoming increasingly apparent (65) thus it is interesting that
our earlier Oxr1 interaction studies identified components of
this particular system under oxidative stress (20). For example,
RAN (a member of the RAS oncogene family), one such putative
Oxr1 binding partner, is a small GTPase and an essential
regulator of nuclear import. Specifically, it has been established
that RAN is required for the normal nuclear localization of TDP-
43 (66) in concert with a feedback loop whereby TDP-43 can
regulate the expression of RAN itself (67). As rescuing TDP-43
mislocalisation may be a critical approach for tackling TDP-
43 proteinopathies, the direct involvement of Oxr1 in these
trafficking processes warrants further investigation in the
future.
With the availability of rodent models of TDP-43-associated
ALS, one valuable experimental strategy is to find modifiers of
disease using a genetic approach (68,69). Here we demonstrate
that Oxr1 is the first antioxidant protein that, when genetically
overexpressed, can not only mitigate TDP-43-associated neuro-
muscular dysfunction in vivo but also improve TDP-43 cytoplas-
mic mislocalization in cultured motor neurons. Taken together,
our results establish Oxr1 as a novel genetic modifier of TDP-43-
related pathology in vivo.
Materials and Methods
Animals
All experiments were conducted in adherence to the guidelines
set forth by the UK Home Office regulations, and with the
approval of the University of Oxford Ethical Review Panel. Trans-
genic TDP-43M337V BAC mice, overexpressing a YPET-tagged TDP-
43 protein harbouring the M337V mutation, were maintained
on a C57BL/6 J background. Transgenic TDP-43M337V BAC mice
are available from The Jackson Laboratory as strain JAX#029266
(https://www.jax.org/strain/029266). Tg (Prnp-Oxr1)/− mice,
which were generated by Dr Ben Davies (Wellcome Trust Centre
for Human Genetics) as previously described (21), overexpress
a HA-tagged Oxr1 transgene driven by the mouse neuronal
specific-Prnp promoter (70), and had been maintained on a
C57BL/6J background for over 10 generations. For quantitative
behavioural and pathological analyses, breeding schemes
paired hemizygous TDP-43M337V/− males with hemizygous TDP-
43M337V/−/Oxr1Prnp/− females to produce litters consisting of
control NTg and Oxr1Prnp/− mice, and experimental homozygous
TDP-43M337V/M337V and homozygous TDP-43M337V/M337V/Oxr1Prnp/−
animals. Mice from several litters were required to generate
each experimental cohort; for quantitative behavioural and
pathological analyses, all cohorts were age and sex-matched.
For primary motor neuron cultures, breeding schemes paired
homozygous TDP-43M337V/M337V males with Oxr1Prnp/− females
to produce litters consisting of hemizygous TDP-43M337V/− and
hemizygous TDP-43M337V/−/Oxr1Prnp/− mice. The day of plug was
designated as E0.5 and the day of birth was designated as
postnatal day 0 (P0). Mice received food and water ad libitum,
and were housed on a 12-h on/off light cycle.
Behavioural tests
Motor function was tested using a rotarod. In brief, mice were
placed on a beam of a rotarod device facing in an orientation
opposite to rotation. The rod accelerated from 5 to 40 rpm over
a 5-min period and the time latency to fall from the rod (or
two full rotations on the rod without an attempt to continue
running) was recorded. Mice were tested for one trial each day
for three consecutive days at each experimental time point and
an average time for the three trials was calculated. To test for
muscle strength, mice were placed on a metal mesh grid, which
was gently inverted such that the mice gripped on in an upside-
down orientation. The grid was held fixed at a height of 40 cm
above a horizontal surface and the time latency to fall from the
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Histology
For fresh frozen tissue collection, mice were sacrificed by cervical
dislocation. For perfused tissue collection, mice were given a
lethal intraperitoneal injection of pentobarbitone, followed by
transcardial perfusion with 0.9% saline and fixation with 4%
paraformaldehyde (PFA). Spinal cords were dissected, post-fixed
overnight in 4% PFA at 4◦C, cryoprotected with 30% sucrose and
mounted in O.C.T. (VWR, Lutterworth, UK) medium. Hind-limb
muscle was freshly dissected and frozen in O.C.T. medium on
isopentane in liquid nitrogen. Frozen transverse sections were
cut on a cryostat (Leica, Newcastle upon Tyne, UK) at 10 μm for
muscle and 15 μm for spinal cord. For haematoxylin and eosin
stain, muscle sections were air dried and placed in haematoxylin
for 10 min, and briefly washed in distilled water. Sections were
subsequently bled in 70% ethanol/0.1% hydrochloric acid for 10 s,
and washed in distilled water. Sections were then placed in eosin
for 2 min, washed in distilled water, dehydrated and mounted.
For Nissl staining, spinal cord sections were air dried, fixed in
100% ethanol and hydrated with a series of decreasing alcohol
dilutions for 30 s each until washing in distilled water. Sections
were subsequently stained for 3 min with 0.5% Cresyl violet
(Sigma, Poole, UK.) solution and rinsed in distilled water. Sections
were then dehydrated and mounted.For motor neuron counts,all
large ventral horn motor neurons on at least 16 matched nissl-
stained sections of lumbar spinal cord segments (L1–L6) were
counted. For differential ATPase staining, muscle sections were
preincubated in 20 mm sodium barbital, 36 mm CaCI2, pH 10.3
for 15 min or 50 mm sodium acetate, 30 mm sodium barbital
pH 4.2 for 5 min. After rinsing in distilled water, the sections
were incubated for 25 min in 20 mm sodium barbital, pH 9.5,
containing 9 mm CaCl2 and 2.7 mm ATP and then washed in
three changes of 1% CaCl2 (3 min each). Next, the sections were
immersed for 10 min in 2% CoCl2 before washing in five changes
of 5 mm sodium barbital. After staining with 1% (NH4)2S for 30 s,
the sections were washed with several changes of tap water,
and mounted using Aquamount (Life Technologies, Paisley, UK).
For quantification, three transverse whole muscle sections at
400 μM intervals were analysed from three to five male animals
of each genotype, with adjacent sections used for comparative
pH 4.2 and pH 10.3 staining. Images were viewed on a Zeiss
Axioskop 2 microscope, acquired using an AxioCam HR digital
camera (Zeiss, Cambridge, UK), and processed using AxioVision
software (Zeiss).
Immunohistochemistry
For all immunohistochemistry, perfused tissue sections were
subjected to antigen-retrieval by boiling in 0.2% sodium citrate
buffer for 20 min in a microwave and washed in ddH2O.
Endogenous peroxidase activity was first removed by incubating
in H2O2/methanol for 15 min at room temperature (RT) then
washing in PBS. Spinal cord sections were blocked in 5%
normal goat serum (NGS)/PBS/0.5% Tween-20 at RT for 1 h.
For other immunohistochemistry, sections were blocked in
5% NGS/PBS/0.3% Triton-X. Incubation with following primary
antibodies and dilutions were conducted overnight at 4◦C:
rabbit anti-TDP-43 (1:2500, 10 782-2-AP, ProteinTech, Manchester,
UK); rabbit anti-GFAP (1:500, ab7260, Abcam, Cambridge, UK);
rabbit anti-Iba1 (1:500, 019–19 741, Wako, Osaka, Japan). Sections
were then incubated with a biotinylated goat anti-rabbit IgG
secondary antibody (Vector Laboratories, Peterborough, UK) at
1:200 for 2 h at RT, washed in PBS three times for 5 min each
followed by incubation with an avidin-biotinylated peroxidase
complex for 1 h kit). Sections were then washed in PBS three
times for 5 min each and then incubated in Impact 3, 3′-
diaminobenzidine solution (Vector Laboratories) for 2 min,
immediately washed in ddH2O for 5 min, dehydrated and
mounted using Histomount (National Diagnostics, Atlanta, GA).
Images were viewed on a Zeiss Axioskop 2 microscope, acquired
using an AxioCam HR digital camera (Zeiss), and processed
using AxioVision software (Zeiss). For inflammatory marker
quantification, three matched sections from the lumbar spinal
cord (L4–5) were processed and quantified in parallel using
ImageJ for the total immunopositive area and the number of
cells from the number of visible cell bodies.
Immunoblotting
Tissue extracts were prepared in RIPA buffer (50 mm Tris pH 7.5,
150 mm NaCl, 0.1% SDS, 0.5% Na-deoxycholate, 1% triton) for
immunoblotting (IB). Protein concentrations were quantified
using BCA assay (Life Technologies). For IB, Laemmli sample
buffer was added to 50 μg protein samples and boiled for 5 min,
separated on 12% SDS PAGE, and transferred to PVDF membranes
(Amersham, Amersham, UK). Membranes were subsequently
blocked with 5% skimmed milk in PBS/0.5% Tween-20 (PBST) for
1 h at RT, before incubation with primary antibody overnight at
4◦C. The following primary antibodies and dilutions were used:
rabbit anti-HA (IB: 1:1000, H6908, Sigma); rabbit anti-Oxr1 (IB:
1:5000/CoIP: 1:250, (71)); rabbit anti-TDP-43 (1:1000, 10 782-2-AP,
ProteinTech, Manchester, UK); rabbit anti-GFP (1:1000, A-11122,
Invitrogen, Paisley, UK); mouse anti-GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase, 1:1000, 649 201 Biolegend, San Diego,
CA). After washing with PBST, membranes were incubated with
HRP-conjugated anti-rabbit (1:5000, NA934-100UL, Amersham)
or anti-mouse (1:5000, NA931-100UL, Amersham) secondary
antibodies, and blots were developed using ECL reagents
(Amersham). When required, the integrated optical density of
each band was measured in ImageJ and expression normalized
to GAPDH loading control levels in the same samples for
comparative expression assessment.
Lumbrical muscle dissection and NMJ analysis
Hind-paw lumbrical muscles were dissected as previously
described (41). Muscles were permeabilized in 96-well plates
with 2% Triton X-100 in PBS for 30 min. After blocking in 4%
(w/v) BSA and 1% Triton X-100 in PBS for 30 min, samples were
incubated with primary antibodies against neurofilament [2H3,
1:50, supernatant, mouse, developmental studies hybridoma
bank (DSHB, Iowa City, IO)] and synaptic vesicles (SV2, 1:100,
concentrate, mouse, DSHB) overnight at 4◦C in blocking solution.
Muscles were washed three times in PBS for 30 min before
incubation for 2 h with Alexa Fluor 488 secondary antibody
(1:200) and 1.5 μg/ml tetramethylrhodamine α-BTX (BT00012,
Cambridge Bioscience, Cambridge, UK) dilution in PBS. Finally,
muscles were washed three times for 30 min in PBS, and
mounted with Mowiol mounting medium (475 904, Calbiochem,
Watford, UK). For denervation analysis, NMJs were viewed
using an Axioskop 2 microscope and were scored as being
fully innervated (full overlap between the pre-synaptic nerve
terminal and the post-synaptic endplate), partially innervated
(>80% of regions of the post-synapse lacking neuronal input)
or vacant (no pre-synaptic staining overlaying the endplate) as
previously described (41,72). A Leica TCS SP5 confocal micro-
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and a 63×/1.4NA Plan-Apo oil immersion objective was used
to image representative examples of NMJ denervation and also
NMJs for endplate analysis. Z-stacks were projected into single
images using Leica Application Suite software and the resulting
‘collapsed’ images were used for all analyses. Only NMJs with
clearly visible presynaptic axons were scored. To measure NMJ
area, the perimeter circumscribing the postsynaptic staining
from ‘collapsed’ Z-stack images (24 sections, 0.5 μm step size
intervals, 11.6 μm total stack depth) was drawn by hand and
the enclosed surface area measured using ImageJ as performed
previously (41). ≥57 NMJs were scored per mouse for denervation
analysis and 30–50 NMJs per mouse were scored for NMJ
endplate analysis.
Primary motor neuron culture and
immunocytochemistry
To culture primary motor neurons, whole spinal cords were dis-
sected from TDP-43M337V/− and TDP-43M337V/-Oxr1Prnp/− embryos
at E13.5. Spinal cords were digested in trypsin solution (Gibco)
for 10 min at 37◦C, followed by incubation with trypsin inhibitor
(0.8 mg/ml; Sigma) for 5 min at RT. Spinal cords were then
transferred to motor neuron growth medium (MNGM) that con-
sisted of Neurobasal medium (Invitrogen, Paisley, UK) supple-
mented with 10% horse serum (heat inactivated; Invitrogen),
1% B27 supplement (Invitrogen) and 1% Glutamax I (Invitrogen).
After cell trituration, the dissociated spinal cord cell suspen-
sion was subsequently passed through a 40 μm cell strainer.
Purification of motor neurons was performed using Optiprep
density 1.32 (Sigma) in MNGM and density gradient centrifuga-
tion, as described previously (64). After washing motor neurons
in fresh MNGM, motor neurons were seeded at a density of
20 000 cells/cm2 on sterilized glass coverslips (Life Technolo-
gies) pre-coated in poly-L-ornithine (Sigma). Motor neurons were
allowed to attach in a humidified 37◦C/5% CO2 incubator for
1 h, before MNGM was replaced with fresh MNGM supplemented
with 10 ng/ml brain derived neurotrophic factor (PeproTech,
London, UK), glial-cell derived neurotrophic factor (PeproTech),
neurotrophin-3 (PeproTech) and 25 ng/ml of ciliary neurotrophic
factor (PeproTech). Cultured motor neurons were allowed to
expand for 7 days in vitro (DIV) prior to assaying.
For immunocytochemistry, motor neuron cultures were fixed
in 4% PFA in PBS (pH 7.2) for 10 min. Motor neurons were
then washed in PBS three times for 15 min, and blocked and
permeabilized for 1 h in PBS containing 5% NGS and 0.5% Triton
X-100. Incubation with the following primary antibodies and dilu-
tions was conducted overnight at 4◦C: mouse anti-SMI32 (1:1000:
801 701, Biolegend); rabbit anti-GFP (1:200: A-11122, Invitrogen).
After washing in PBS, coverslips were incubated with AlexaFluor
secondary antibodies for 2 h at RT. After three washes in PBS,
motor neurons were mounted with DAPI-containing Vectashield
mounting medium. Cultures were imaged using a Leica TCS SP5
confocal microscope. All Images were processed in ImageJ and
only cells positive for SMI32 were further analysed. To calculate
cytoplasmic localization of YPET-tagged human TDP-43M337V, the
perimeters circumscribing both the external membrane of the
cytoplasm of the entire neuron and the nucleus were drawn by
hand and GFP fluorescence intensity was recorded in both areas
of the cell. The proportion of TDP-43 cytoplasmic localization
was calculated as: (intensity of cytoplasmic signal/intensity
of nuclear and cytoplasmic signal). Between 45 and 60 motor
neurons were used for protein localization analysis per individual
embryonic motor neuron preparation. Cultures from six embryos
from at least two independent litters were analysed per genotype.
Statistical analysis
Results were analysed using Prism (GraphPad Software, Inc.
San Diego, CA) with the statistical tests as described in the
figure legends. Data are presented as mean ± SEM (standard
error of mean), with N indicating the number of independent
biological replicates used in each group for comparison. For all
quantitative data, experimenters were blinded to the genotypes.
To determine the sample sizes used for each experiment,
power calculations were carried out (73) using our own datasets
of the same type (stated as: standard deviation/target effect
size given as percentage difference between experimental
groups/sample size using a significance value of P < 0.05 and
power level of 80%). Figure 1B: 6/20/N = 3; Figure 2A-B: 20/15/N = 6;
Figure 2C and D: 20/25/N = 6; Figure 2E and F: 2/10/N = 5; Figure 3:
5/15/N = 3; Figure 4: 50/20/N = 3; Figure 5A and B: 1/40/N = 3;
Figure 6B: 2/25/N = 3; Figure 6C and D: 0.3/50/N = 3.
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Supplementary Material is available at HMG online.
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